Farhad Ravandi
Impact in
- Hematology top 0.01%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Hematopoietic Stem Cell Transplantation
- Genetics top 0.02%
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Papers in
- Hematology 1.0k
- Acute Myeloid Leukemia Research 748
- Chronic Myeloid Leukemia Treatments 439
- Multiple Myeloma Research and Treatments 82
- Genetics 529
- Chronic Lymphocytic Leukemia Research 360
- Myeloproliferative Neoplasms: Diagnosis and Treatment 157
- Co-authors
- Hagop M. Kantarjian (251 shared papers)Jörge E. Cortes (251 shared papers)Guillermo Garcia‐Manero (251 shared papers)Elias Jabbour (251 shared papers)Gautam Borthakur (251 shared papers)Susan O’Brien (251 shared papers)Tapan M. Kadia (251 shared papers)Stefan Faderl (239 shared papers)
- Journals
- Blood (561 papers)Journal of Clinical Oncology (153 papers)Cancer (96 papers)American Journal of Hematology (63 papers)British Journal of Haematology (26 papers)
- Partner nations
- United StatesGermanyUnited Kingdom
In The Last Decade
Farhad Ravandi
1.2k papers receiving 35.8k citations
Farhad Ravandi's Hit Papers
Peers
Comparison fields: 5 of 154
- Hematology 24.2k
- Genetics 8.9k
- Public Health, Environmental and Occupational Health 8.4k
- Oncology 6.6k
- Molecular Biology 11.9k
Countries citing papers authored by Farhad Ravandi
This map shows the geographic impact of Farhad Ravandi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Farhad Ravandi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Farhad Ravandi more than expected).
Fields of papers citing papers by Farhad Ravandi
This network shows the impact of papers produced by Farhad Ravandi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Farhad Ravandi. The network helps show where Farhad Ravandi may publish in the future.
Co-authors
The 25 scholars most cited alongside Farhad Ravandi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 1.3k papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Decitabine improves patient outcomes in myelodysplastic syndromes Hit paper breakdown → | 2006 | 1200 |
| 2 | Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia Hit paper breakdown → | 2012 | 854 |
| 3 | Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia Hit paper breakdown → | 2006 | 550 |
| 4 | Acute myeloid leukemia: current progress and future directions Hit paper breakdown → | 2021 | 495 |
| 5 | 2006 | 404 | |
| 6 | 2008 | 361 | |
| 7 | Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study Hit paper breakdown → | 2012 | 323 |
| 8 | 2010 | 319 | |
| 9 | 2007 | 314 | |
| 10 | 2017 | 302 | |
| 11 | 2010 | 301 | |
| 12 | 2013 | 296 | |
| 13 | 2010 | 292 | |
| 14 | 2008 | 284 | |
| 15 | 2006 | 280 | |
| 16 | 2016 | 262 | |
| 17 | Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges Hit paper breakdown → | 2020 | 260 |
| 18 | 2007 | 258 | |
| 19 | 2010 | 252 | |
| 20 | 2011 | 252 |
About Farhad Ravandi
Farhad Ravandi is a scholar working on Hematology, Genetics, Public Health, Environmental and Occupational Health, Molecular Biology and Oncology, having authored 1.3k papers that have together received 36.5k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (748 papers), Chronic Myeloid Leukemia Treatments (439 papers), Acute Lymphoblastic Leukemia research (365 papers), Chronic Lymphocytic Leukemia Research (360 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (157 papers), Histone Deacetylase Inhibitors Research (120 papers), Lymphoma Diagnosis and Treatment (87 papers) and Multiple Myeloma Research and Treatments (82 papers). The work is most often cited by research in Hematology (24.2k citations), Genetics (8.9k citations), Public Health, Environmental and Occupational Health (8.4k citations), Oncology (6.6k citations) and Molecular Biology (11.9k citations). Farhad Ravandi has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Hagop M. Kantarjian, Jörge E. Cortes, Guillermo Garcia‐Manero, Elias Jabbour, Gautam Borthakur, Susan O’Brien, Tapan M. Kadia, Stefan Faderl, Marina Konopleva and Naval Daver. Their work appears in journals such as Blood, Journal of Clinical Oncology, Cancer, American Journal of Hematology and British Journal of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.